In the Invited Commentary titled “Prehospital Tranexamic Acid: STAAMP of Approval or Return to Sender?”1 published online October 5, 2020, in JAMA Surgery, in the first sentence referring to the CRASH trials, the acronym was incorrectly expanded as “Corticosteroid Randomisation After significant head Injury.” The sentence now specifies the CRASH-2 trial, and the acronym has been corrected to read “Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage.”